Cancer Pain Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | WEX Pharmaceuticals, Tetra Bio-pharma, Johnson & Johnson, Cephalon, Sanofi, Grünenthal

Posted on
by

Cancer Pain Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | WEX Pharmaceuticals, Tetra Bio-pharma, Johnson & Johnson, Cephalon, Sanofi, Grünenthal
DelveInsight’s “Cancer Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cancer Pain.

DelveInsight’s “Cancer Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cancer Pain, historical and forecasted epidemiology as well as the Cancer Pain market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Cancer Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Pain Market Forecast

 

Some of the key facts of the Cancer Pain Market Report: 

  • The Cancer Pain market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2021, there were 2,278,000 cases of cancer pain in the EU4 and the UK; this number is expected to rise over the predicted period
  • Germany had the most cancer pain instances among the EU4 nations, with 634,000 cases in 2021 and an expected rise to 678,000 cases by 2032
  • In 2021, on the basis of etiology, the cases of cancer pain having direct tumor involvement, associated with cancer treatment, not related to cancer or cancer therapy were ~1,401,000, ~729,000 and ~148,000 respectively in EU4 and the UK
  • Key Cancer Pain Companies: Sorrento Therapeutics, WEX Pharmaceuticals, Tetra Bio-pharma, Johnson & Johnson, Cephalon, Sanofi, Grünenthal GmbH, MetaPhore Pharmaceuticals, Celgene Corporation, Archimedes Pharma, Tris Pharma, Inc., and others
  • Key Cancer Pain Therapies: Resiniferatoxin, Tetrodotoxin, QIXLEEF, PPP001, Hydromprphone, SSR411298, Tapentadol, M40403, Lenalidomide, Fentanyl, Cebranopadol, and others
  • The Cancer Pain epidemiology based on gender analyzed that Cancer pain affects males and female equally
  • The Cancer Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Pain pipeline products will significantly revolutionize the Cancer Pain market dynamics.

 

Cancer Pain Overview

Pain is “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage,” according to the International Association for the Study of Pain. Cancer affects a large number of individuals worldwide, and its frequency is increasing.

 

Get a Free sample for the Cancer Pain Market Report –

https://www.delveinsight.com/sample-request/cancer-pain-market

 

Cancer Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Cancer Pain Epidemiology Segmentation:

The Cancer Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Cancer Pain
  • Prevalent Cases of Cancer Pain by severity
  • Gender-specific Prevalence of Cancer Pain
  • Diagnosed Cases of Episodic and Chronic Cancer Pain

 

Download the report to understand which factors are driving Cancer Pain epidemiology trends @ Cancer Pain Epidemiology Forecast

 

Cancer Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Pain market or expected to get launched during the study period. The analysis covers Cancer Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cancer Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Cancer Pain Therapies and Key Companies

  • Resiniferatoxin: Sorrento Therapeutics
  • Tetrodotoxin: WEX Pharmaceuticals
  • QIXLEEF: Tetra Bio-pharma
  • PPP001: Tetra Bio-Pharma
  • Hydromprphone: Johnson & Johnson
  • Fentanyl Buccal: Cephalon
  • SSR411298: Sanofi
  • Tapentadol: Grünenthal GmbH
  • M40403: MetaPhore Pharmaceuticals
  • Lenalidomide: Celgene Corporation
  • Fentanyl: Archimedes Pharma
  • Cebranopadol: Tris Pharma, Inc.

 

Discover more about therapies set to grab major Cancer Pain market share @ Cancer Pain Treatment Market

 

Cancer Pain Market Drivers

  • The increasing prevalence of cancer cases worldwide and the rise in awareness regarding cancer-associated pain being experienced by patients will drive the overall cancer pain therapeutics market in the upcoming years
  • Opioids are necessary for the majority of cancer patients, but serious side effects and addiction-related concerns are associated with it. With the expected launch of drugs like tetrodotoxin and resiniferatoxin, the market will experience a major shift toward the senonopioid-based medications for treating cancer pain

 

Cancer Pain Market Barriers

  • There has been no approval in recent years for cancer pain; therefore, companies working on this indication have a significant opportunity to penetrate the cancer pain management market
  • Opioids dominate cancer pain treatment; companies like Wex Pharmaceuticals, Tetra Bio-Pharma, Sorrento Therapeutics, and others are developing nonopioid candidates for cancer pain. Therelies great potential for pharmaceutical companies to come up with novel treatment mechanisms for cancer pain management

 

Scope of the Cancer Pain Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Cancer Pain Companies: Sorrento Therapeutics, WEX Pharmaceuticals, Tetra Bio-pharma, Johnson & Johnson, Cephalon, Sanofi, Grünenthal GmbH, MetaPhore Pharmaceuticals, Celgene Corporation, Archimedes Pharma, Tris Pharma, Inc., and others
  • Key Cancer Pain Therapies: Resiniferatoxin, Tetrodotoxin, QIXLEEF, PPP001, Hydromprphone, SSR411298, Tapentadol, M40403, Lenalidomide, Fentanyl, Cebranopadol, and others
  • Cancer Pain Therapeutic Assessment: Cancer Pain current marketed and Cancer Pain emerging therapies
  • Cancer Pain Market Dynamics: Cancer Pain market drivers and Cancer Pain market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Cancer Pain Unmet Needs, KOL’s views, Analyst’s views, Cancer Pain Market Access and Reimbursement 

 

To know more about Cancer Pain companies working in the treatment market, visit @ Cancer Pain Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Cancer Pain Market Report Introduction

2. Executive Summary for Cancer Pain

3. SWOT analysis of Cancer Pain

4. Cancer Pain Patient Share (%) Overview at a Glance

5. Cancer Pain Market Overview at a Glance

6. Cancer Pain Disease Background and Overview

7. Cancer Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Cancer Pain 

9. Cancer Pain Current Treatment and Medical Practices

10. Cancer Pain Unmet Needs

11. Cancer Pain Emerging Therapies

12. Cancer Pain Market Outlook

13. Country-Wise Cancer Pain Market Analysis (2019–2032)

14. Cancer Pain Market Access and Reimbursement of Therapies

15. Cancer Pain Market Drivers

16. Cancer Pain Market Barriers

17.  Cancer Pain Appendix

18. Cancer Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services